Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics


Rhythm Pharmaceuticals, Inc. (RYTM): $20.41

-0.30 (-1.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RYTM Stock Price Chart Interactive Chart >

Price chart for RYTM

RYTM Price/Volume Stats

Current price $20.41 52-week high $43.26
Prev. close $20.71 52-week low $18.00
Day low $20.22 Volume 149,682
Day high $20.90 Avg. volume 415,620
50-day MA $20.71 Dividend yield N/A
200-day MA $25.44 Market Cap 1.02B

Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio


Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.


RYTM Latest News Stream


Event/Time News Detail
Loading, please wait...

RYTM Latest Social Stream


Loading social stream, please wait...

View Full RYTM Social Stream

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12 noon ET. A live audio webcast of the presentation will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation. About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to...

Yahoo | May 27, 2021

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

European Commission decision anticipated in JulyBOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for setmelanotide for the treatment of obesity and the control of hunger associated with confirmed loss-of-function biallelic proopiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. “People living with these rare genetic diseases experience early-on...

Yahoo | May 21, 2021

Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference

BOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 4:15 p.m. ET. A live audio webcast of the fireside chat will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation. About Rhythm PharmaceuticalsRhythm is a commercial-stage bi...

Yahoo | May 5, 2021

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 4600.00% and -99.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 3, 2021

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome -- -- Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies -- -- Closed $172.5 million public offering and sold Priority Review Voucher for $100 million, providing additional funding to advance continued development of setmelanotide -- BOSTON, May 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company co...

Yahoo | May 3, 2021

Read More 'RYTM' Stories Here

RYTM Price Returns

1-mo -4.94%
3-mo -20.21%
6-mo -28.74%
1-year -6.55%
3-year -22.01%
5-year N/A
YTD -31.35%
2020 29.49%
2019 -14.58%
2018 -7.50%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8987 seconds.